Navigation Links
Schering-Plough Reports Financial Results for Third Quarter of 2008
Date:10/21/2008

Strong Financial Performance Driven By Strength and Diversity on Many Fronts; Productivity Transformation Taking Hold

KENILWORTH, N.J., Oct. 21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported financial results for the third quarter of 2008.

"Our performance this quarter again demonstrates the strength of our long-term strategies and our ability to execute on them," said Fred Hassan, chairman and CEO. "Despite a tough environment and challenges to the U.S. cholesterol joint venture products, we delivered strong sales and earnings while investing in R&D and paying down debt. Thanks to the new strength and diversity we have built on many fronts, we have continued to grow our top line, grow our pipeline, reduce costs and invest wisely."

Hassan added, "Now with almost one year of experience, we are seeing that the acquisition of Organon BioSciences (OBS) is resulting in a powerful combination. This integration is creating new product strength, new geographic strength, new strength with our customers and new R&D strength - including a late-stage pipeline that is now one of the strongest in our industry."

For the 2008 third quarter, Schering-Plough reported net income available to common shareholders of $551 million or 34 cents per common share on a GAAP basis. Earnings per common share for the 2008 third quarter would have been 39 cents on a reconciled basis, which excludes purchase accounting adjustments, special and acquisition-related items, a $160 million pre-tax gain on previously announced divestitures of certain animal health products and $19 million of income from the termination of a respiratory joint venture with Merck. For the 2007 third quarter, Schering-Plough reported net
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine news :

1. Schering-Plough Announces Transition of Animal Health Leadership
2. Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
3. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
4. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
5. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
6. Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management
7. Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference
8. Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain
9. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
10. Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough
11. Schering-Plough CEO to Buy $2 Million in Common Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... is a professional supplier of funeral products. According to the ... in the global market. Recently, the company has announced its ... special offer for all the newly released items. , ... are made with superb materials. As is commonly noted, a ... to the departed saint. MillionaireCasket.com is always here to help. ...
(Date:7/13/2014)... to get the best treatment and variations in the ... survival for blood cancer patients still varies widely between ... of survival in European adults to date, published in ... is that 5-year survival for most cancers of the ... likely reflecting the approval of new targeted drugs in ...
(Date:7/13/2014)... Carolinas Healthcare System celebrated today the ... HealthCare System - Anson located in Anson County. The ... Hospital in Wadesboro. , Located on U.S. Highway 74, ... previous facility. Situated on a 10-acre site, the new ... room drop-off, helipad, healing garden, and 15 beds. With ...
(Date:7/13/2014)... identifies a novel genetic and molecular pathway in ... up potential new therapeutic strategies for an enigmatic ... a chronic inflammatory disorder of the esophagus. The ... foods and an over-accumulation in the esophagus of ... body,s immune system). EoE can cause a variety ...
(Date:7/13/2014)... 2014 Chromatography system is a ... various types of biological samples such as air ... mixture into two phase, namely mobile phase and ... run over the stationary phase, followed by the ... provide the separation of mixture. Chromatography system plays ...
Breaking Medicine News(10 mins):Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3
... fibronectin can predict whether a pregnant woman is at ... risk for pre-term births are women with previous pre-term ... suffer from diabetes and/or hypertension. The current approach for ... is the use of a clinical scoring system, ...
... technology born of genetic ,engineering, and known as naked ... such as multiple ,sclerosis and rheumatoid arthritis. , ... In multiple sclerosis (MS) and ,rheumatoid arthritis (RA), the ... myelin sheath of nerves falls ,victim, while in RA, ...
... requiring heart bypass ,speeds recovery in children undergoing ... clinical trial published in The Lancet., , ... underwent long and difficult surgeries. Following trauma or ... concentrations plummet. Many experts thought this was an ...
... derivatives from garlic may potentially play a role in ... review published in a recent issue of Nutrition in ... effect of garlic on risk factors for heart disease. ... LDL ("bad") ,cholesterol and blood pressure. It may also ...
... painkillers to ease the agony of terminally ill patients ... the practice, comparing it to euthanasia, but doctors at ... doses of drugs such as morphine live just as ... research published in The Lancet medical journal, they compared ...
... Antibiotcs seem to treat or prevent the symptoms of autism ... is affected by autism. Currently there are no treatments for ... found that a subset of patients with autism who experience ... by antibiotic vancomycin. ,Interestingly the study was done ...
Cached Medicine News:
(Date:7/11/2014)... On Thursday, July 10, 2014, the ... Industrial Average finished the day 0.42% lower at 16,915.07, and ... were broad based as eight out of ten sectors ended ... Index ended the day at 711.88, down 0.02%, while the ... has initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... , , , Funding and ... NEW YORK, Dec. 14 The Microbicides Development Programme announced ... conducted among almost 9,400 women in four African countries, found ... of HIV infection. , Reacting to today,s announcement, AVAC executive ...
... InterMune, Inc. (Nasdaq: ITMN ) today announced that Steve ... the 2009 DB-Biotech Boston Confab on December 15, 2009 at ... audio webcast of the presentation, investors and other interested parties ... corporate website at www.intermune.com. The company recommends logging on ...
Cached Medicine Technology:AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial 2AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial 3
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established.,NOTE: Use of a heavy-duty wire guide is recommended....
Medicine Products: